Zealand Pharma to Participate in Jefferies London Healthcare Conference
Zealand Pharma announces its participation in the Jefferies London Healthcare Conference scheduled for November 18, 2021. Members of the senior management team will present at 3:00 a.m. EST (8:00 a.m. GMT). A pre-recorded webcast will be available on the company's website at the time of the presentation. Zealand Pharma specializes in developing peptide-based medicines, with more than 10 drug candidates in clinical development, two already on the market, and three in late-stage development, alongside partnerships with Boehringer Ingelheim and AstraZeneca.
- Participation in a notable healthcare conference, enhancing visibility.
- More than 10 drug candidates in clinical development indicate a strong pipeline.
- Partnerships with Boehringer Ingelheim and AstraZeneca expand potential market reach.
- None.
Company announcement – No. 68 / 2021
Zealand Pharma to Participate in Jefferies London Healthcare Conference
Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the Jefferies London Healthcare Conference:
Jefferies London Healthcare Conference
Date: Thursday, November 18, 2021
Presentation: 3:00 a.m. EST / 8:00 a.m. GMT / 9:00 a.m. CET
A pre-recorded webcast of the presentation will be available at the time of the presentation on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Maeve Conneighton |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What is Zealand Pharma's participation in the Jefferies London Healthcare Conference?
Where can I watch Zealand Pharma's conference presentation?
How many drug candidates does Zealand Pharma have in development?
Which companies does Zealand Pharma collaborate with?
